Development of Personalized Combination Cancer Immunotherapy Based on the Patients’ Immune Status
- 1 January 2015
- book chapter
- Published by Springer Science and Business Media LLC
Abstract
No abstract availableKeywords
This publication has 35 references indexed in Scilit:
- Towards the introduction of the ‘Immunoscore’ in the classification of malignant tumoursThe Journal of Pathology, 2013
- Spatiotemporal Dynamics of Intratumoral Immune Cells Reveal the Immune Landscape in Human CancerImmunity, 2013
- Safety and Activity of Anti–PD-L1 Antibody in Patients with Advanced CancerNew England Journal of Medicine, 2012
- The immune contexture in human tumours: impact on clinical outcomeNature Reviews Cancer, 2012
- T Cells with Chimeric Antigen Receptors Have Potent Antitumor Effects and Can Establish Memory in Patients with Advanced LeukemiaScience Translational Medicine, 2011
- Enhanced Cancer Immunotherapy Using STAT3-Depleted Dendritic Cells with High Th1-Inducing Ability and Resistance to Cancer Cell-Derived Inhibitory FactorsPublished by The American Association of Immunologists ,2011
- Improved Survival with Ipilimumab in Patients with Metastatic MelanomaNew England Journal of Medicine, 2010
- Identification of a human melanoma antigen recognized by tumor-infiltrating lymphocytes associated with in vivo tumor rejection.Proceedings of the National Academy of Sciences, 1994
- Identification of the immunodominant peptides of the MART-1 human melanoma antigen recognized by the majority of HLA-A2-restricted tumor infiltrating lymphocytes.The Journal of Experimental Medicine, 1994
- Cloning of the gene coding for a shared human melanoma antigen recognized by autologous T cells infiltrating into tumor.Proceedings of the National Academy of Sciences, 1994